期刊
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
卷 37, 期 2, 页码 397-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.iac.2017.01.012
关键词
Biologic agents; Monoclonal antibodies; Infusion reaction; Delayed reaction; Drug desensitization; Omalizumab; Rituximab
Biologic therapies are emerging as a significant therapeutic option for many with debilitating inflammatory and autoimmune conditions. As expansion in the number of FDA-approved agents continue to be seen, more unanticipated adverse reactions are likely to occur. Currently, the diagnostic tools, including skin testing and in vitro testing, to evaluate for immediate hypersensitivity reactions are insufficient. In this review, management strategies for common acute infusion reactions, injection site reactions, and immediate reactions suggestive of IgE-mediated mechanisms are discussed. Desensitization can be considered for reactions suggestive of IgE-mediated mechanisms, but allergists/immunologists should be involved in managing these patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据